KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Invested Capital (2019 - 2025)

Historic Return on Invested Capital for Alnylam Pharmaceuticals (ALNY) over the last 9 years, with Q4 2025 value amounting to 0.85%.

  • Alnylam Pharmaceuticals' Return on Invested Capital rose 22000.0% to 0.85% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.85%, marking a year-over-year increase of 22000.0%. This contributed to the annual value of 1.03% for FY2025, which is 33400.0% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Return on Invested Capital of 0.85% as of Q4 2025, which was up 22000.0% from 8.28% recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Return on Invested Capital peaked at 8.28% during Q3 2025, and registered a low of 13.29% during Q3 2024.
  • In the last 5 years, Alnylam Pharmaceuticals' Return on Invested Capital had a median value of 0.53% in 2022 and averaged 0.17%.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Return on Invested Capital crashed by -145500bps in 2024, and later surged by 215700bps in 2025.
  • Alnylam Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.58% in 2021, then surged by 1307bps to 6.98% in 2022, then tumbled by -79bps to 1.48% in 2023, then plummeted by -191bps to 1.35% in 2024, then surged by 163bps to 0.85% in 2025.
  • Its last three reported values are 0.85% in Q4 2025, 8.28% for Q3 2025, and 0.49% during Q2 2025.